AR105459A1 - Derivados de pirrolo[2,1-f][1,2,4]triazina útiles para tratar trastornos relacionados con kit y pdfgr - Google Patents
Derivados de pirrolo[2,1-f][1,2,4]triazina útiles para tratar trastornos relacionados con kit y pdfgrInfo
- Publication number
- AR105459A1 AR105459A1 ARP160102250A ARP160102250A AR105459A1 AR 105459 A1 AR105459 A1 AR 105459A1 AR P160102250 A ARP160102250 A AR P160102250A AR P160102250 A ARP160102250 A AR P160102250A AR 105459 A1 AR105459 A1 AR 105459A1
- Authority
- AR
- Argentina
- Prior art keywords
- monocyclic
- cycloalkyl
- alkyl
- bicyclic
- heterocyclyl
- Prior art date
Links
- FYADHXFMURLYQI-UHFFFAOYSA-N 1,2,4-triazine Chemical compound C1=CN=NC=N1 FYADHXFMURLYQI-UHFFFAOYSA-N 0.000 title 1
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 title 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 17
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 12
- 125000005843 halogen group Chemical group 0.000 abstract 8
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 7
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 6
- 125000004429 atom Chemical group 0.000 abstract 6
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 6
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 5
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 abstract 4
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 4
- -1 -N (R1) (R1) Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000000304 alkynyl group Chemical group 0.000 abstract 2
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 abstract 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
- 150000003573 thiols Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
En la presente se describen compuestos y composiciones útiles para tratar trastornos relacionados con KIT y PDGFR. Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable de este, donde: W se selecciona de hidrógeno y un compuesto de fórmula (2), donde el Anillo A se selecciona de arilo monocíclico o bicíclico, heteroarilo, cicloalquilo y heterociclilo monocíclico o bicíclico; Z se selecciona de alquilo C₁₋₆, cicloalquilo, arilo monocíclico o bicíclico, aralquilo monocíclico o bicíclico, heteroarilo monocíclico o bicíclico, heterociclilo monocíclico o bicíclico, y heterociclilalquilo monocíclico o bicíclico; donde cada alquilo C₁₋₆, cicloalquilo, arilo monocíclico o bicíclico, aralquilo monocíclico o bicíclico, heteroarilo monocíclico o bicíclico, heterociclilo monocíclico o bicíclico, heterociclilalquilo monocíclico o bicíclico se sustituye independientemente con 0 - 5 apariciones de RC; L se selecciona de -N(R¹)-C(O)-, -N(R¹)C(O)N(R¹)-, -N(R¹)C(O)N(R¹)-(alquileno C₁₋₆)-, N(R¹)-(alquileno C₁₋₆)-, -N(R¹)-C(O)-(alquileno C₁₋₆)-, -N(R¹)-S(O)₂, y -N(R¹)-S(O)₂-(alquileno C₁₋₆)-; donde cada alquileno está sustituido independientemente con 0 - 5 apariciones de R²; cada RA se selecciona independientemente de alquilo C₁₋₆, alcoxi C₁₋₆, halo, haloalquilo C₁₋₆, hidroxialquilo C₁₋₆, heteroalquilo C₁₋₆, -N(R¹)(R¹), ciano y -OR¹; cada RB se selecciona independientemente de hidrógeno, alquilo C₁₋₆, cicloalquilo C₁₋₆, hidroxilo, halo, alcoxi C₁₋₆, haloalquilo C₁₋₆, -N(R¹)(R¹) y ciano; cada RC se selecciona independientemente de alquilo C₁₋₆, alquinilo C₁₋₆, halo, heteroalquilo C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, hidroxialquilo C₁₋₆, cicloalquilo, arilo monocíclico o bicíclico, ariloxi monocíclico o bicíclico, aralquilo monocíclico o bicíclico, heterociclilo monocíclico o bicíclico, heterociclilalquilo monocíclico o bicíclico, nitro, ciano, -C(O)R¹, -OC(O)R¹, -C(O)OR¹, -SR¹, -S(O)₂R¹, -S(O)₂-N(R¹)(R¹), -(alquileno C₁₋₆)-S(O)₂-N(R¹)(R¹), -N(R¹)(R¹), -C(O)-N(R¹)(R¹), -N(R¹)(R¹)-C(O)R¹, -(alquileno C₁₋₆)-N(R¹)-C(O)R¹, -NR¹S(O)₂R¹, -P(O)(R¹)(R¹) y -OR¹; donde cada heteroalquilo, haloalquilo, haloalcoxi, alquilo, alquinilo, cicloalquilo, arilo, ariloxi, aralquilo, heterociclilo, heterociclilalquilo se sustituye independientemente con 0 - 5 apariciones de Rᵃ; o 2 RC junto con el o los átomos de carbono a los que están unidos forman un anillo cicloalquilo o heterociclilo sustituido con 0 - 5 apariciones de Rᵃ; cada RD se selecciona independientemente de halo, alquilo C₁₋₆, cicloalquilo C₁₋₆, hidroxilo, halo, alcoxi C₁₋₆, haloalquilo C₁₋₆, -N(R²)(R²) y ciano; cada R¹ se selecciona independientemente de hidrógeno, hidroxilo, halo, tiol, alquilo C₁₋₆, alcoxi C₁₋₆, haloalquilo C₁₋₆, hidroxialquilo C₁₋₆, tioalquilo C₁₋₆, -NRR, cicloalquilo, cicloalquilalquilo, heterociclilo y heterociclilalquilo, donde cada uno de alquilo C₁₋₆, cicloalquilo y heterociclilo se sustituye independientemente con 0 - 5 apariciones de Rᵇ; o 2 R¹ junto con el o los átomos a los que están unidos forman un anillo cicloalquilo o heterociclilo; cada R² se selecciona independientemente de hidroxilo, alquilo C₁₋₆, alcoxilo C₁₋₆, -NRR; o 2 R² junto con el o los átomos a los que están unidos forman un anillo cicloalquilo o heterociclilo; cada Rᵃ y Rᵇ se selecciona independientemente de hidrógeno, halo, ciano, hidroxilo, alcoxilo C₁₋₆, -C(O)R, C(O)OR, alquilo C₁₋₆, haloalquilo C₁₋₆, heteroalquilo C₁₋₆, hidroxialquilo C₁₋₆, -NRR y cicloalquilo, donde cicloalquilo se sustituye con 0 - 5 apariciones de R; cada R se selecciona independientemente de hidrógeno, alquilo C₁₋₆, alcoxilo C₁₋₆, heteroalquilo C₁₋₆, halo, hidroxilo, haloalquilo C₁₋₆, hidroxialquilo C₁₋₆, cicloalquilo y ciano; o 2 R junto con el o los átomos a los que están unidos forman un anillo cicloalquilo o heterociclilo; cada R es hidrógeno, alquilo C₁₋₆, -C(O)-alquilo C₁₋₆, -C(O)-NRR o -C(S)-NRR; y cada q y r es independientemente 0, 1, 2, 3 ó 4.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562196445P | 2015-07-24 | 2015-07-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105459A1 true AR105459A1 (es) | 2017-10-04 |
Family
ID=56555836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102250A AR105459A1 (es) | 2015-07-24 | 2016-07-22 | Derivados de pirrolo[2,1-f][1,2,4]triazina útiles para tratar trastornos relacionados con kit y pdfgr |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10000496B2 (es) |
| EP (1) | EP3325481B1 (es) |
| JP (1) | JP2018521076A (es) |
| KR (1) | KR20180048635A (es) |
| CN (1) | CN108026102A (es) |
| AR (1) | AR105459A1 (es) |
| AU (1) | AU2016297754A1 (es) |
| BR (1) | BR112018001190A2 (es) |
| CA (1) | CA2994819A1 (es) |
| HK (1) | HK1255103A1 (es) |
| IL (1) | IL256978A (es) |
| MX (1) | MX2018001032A (es) |
| PH (1) | PH12018500177A1 (es) |
| RU (1) | RU2018106483A (es) |
| TW (1) | TW201704237A (es) |
| WO (1) | WO2017019442A1 (es) |
| ZA (1) | ZA201801019B (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104540809B (zh) | 2012-07-11 | 2018-12-11 | 蓝印药品公司 | 成纤维细胞生长因子受体的抑制剂 |
| EP2970231A1 (en) | 2013-03-15 | 2016-01-20 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| EP3409674B1 (en) | 2013-10-17 | 2022-04-06 | Blueprint Medicines Corporation | Process for preparing compositions useful for treating disorders related to kit |
| ES2924111T3 (es) | 2013-10-25 | 2022-10-04 | Blueprint Medicines Corp | Inhibidores del receptor del factor de crecimiento de fibroblastos |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| JP2018521076A (ja) * | 2015-07-24 | 2018-08-02 | ブループリント メディシンズ コーポレイション | Ｋｉｔ及びｐｄｇｆｒに関連する疾病を治療するのに有用な化合物 |
| JP6877407B2 (ja) | 2015-08-26 | 2021-05-26 | ブループリント メディシンズ コーポレイション | Ｎｔｒｋ関連障害の治療に有用な化合物および組成物 |
| WO2017079140A1 (en) | 2015-11-02 | 2017-05-11 | Blueprint Medicines Corporation | Inhibitors of ret |
| JP2019500328A (ja) | 2015-11-19 | 2019-01-10 | ブループリント メディシンズ コーポレイション | Ｎｔｒｋに関連する障害の治療のために有用な化合物及び組成物 |
| UY37155A (es) | 2016-03-17 | 2017-10-31 | Blueprint Medicines Corp | Inhibidores de ret |
| CA3020870C (en) | 2016-04-15 | 2024-04-30 | Blueprint Medicines Corporation | Inhibitors of activin receptor-like kinase |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| WO2018183712A1 (en) | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
| HUE057745T2 (hu) * | 2017-04-18 | 2022-06-28 | Lilly Co Eli | Fenil-2-hidroxi-acetilamino-2-metil-fenil vegyületek |
| ES2931537T3 (es) | 2017-10-18 | 2022-12-30 | Blueprint Medicines Corp | Pirrolopiridinas sustituidas como inhibidores de la quinasa similar al receptor de activina |
| CN107868823A (zh) * | 2017-10-31 | 2018-04-03 | 天津协和华美医学诊断技术有限公司 | 一种检测mds/mpn相关基因群的检测试剂盒 |
| MX2020010417A (es) | 2018-04-03 | 2021-01-08 | Blueprint Medicines Corp | Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret. |
| MX2021012469A (es) | 2019-04-12 | 2022-01-18 | Blueprint Medicines Corp | Composiciones y metodos para el tratamiento de enfermedades mediadas por kit y pdgfra. |
| EP3856341B1 (en) | 2019-04-12 | 2023-09-06 | Blueprint Medicines Corporation | Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making |
| BR112022003768A2 (pt) | 2019-08-29 | 2022-08-09 | Hibercell Inc | Compostos inibidores de perk |
| GB201915447D0 (en) * | 2019-10-24 | 2019-12-11 | Johnson Matthey Plc | Polymorphs of avapritinib and methods of preparing the polymorphs |
| MX2022014858A (es) | 2020-05-29 | 2023-02-23 | Blueprint Medicines Corp | Formas solidas de pralsetinib. |
| EP4229060A1 (en) * | 2020-10-14 | 2023-08-23 | Blueprint Medicines Corporation | Compositions and methods for treating kit-and pdgfra-mediated diseases |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| DK1183033T3 (da) * | 1999-05-21 | 2006-06-06 | Bristol Myers Squibb Co | Pyrrolotriazininhibitorer af kinaser |
| ATE396978T1 (de) | 1999-10-07 | 2008-06-15 | Amgen Inc | Triazin-kinase-hemmer |
| EP1750727A2 (en) | 2004-04-23 | 2007-02-14 | Exelixis, Inc. | Kinase modulators and methods of use |
| JP5256047B2 (ja) | 2006-01-27 | 2013-08-07 | シャンハイ ヘンルイ ファーマシューティカル カンパニー リミテッド | ピロロ［３，２−ｃ］ピリジン−４−オン２−インドリノン（ｉｎｄｏｌｉｎｏｎｅ）プロテインキナーゼ阻害剤 |
| JP5185930B2 (ja) * | 2006-07-07 | 2013-04-17 | ブリストル−マイヤーズ スクイブ カンパニー | ピロロトリアジンキナーゼ阻害剤 |
| US8415340B2 (en) | 2007-07-25 | 2013-04-09 | Bristol-Myers Squibb Company | Triazine kinase inhibitors |
| EP2288611B1 (en) | 2008-03-20 | 2013-05-15 | Amgen Inc. | Aurora kinase modulators and method of use |
| WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| AU2010259009A1 (en) | 2009-06-08 | 2012-01-12 | Nantbioscience, Inc. | Triazine derivatives and their therapeutical applications |
| WO2011005119A1 (en) | 2009-07-07 | 2011-01-13 | Pathway Therapeutics Limited | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy |
| WO2011103196A1 (en) | 2010-02-17 | 2011-08-25 | Amgen Inc. | Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain |
| US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| CN104540809B (zh) | 2012-07-11 | 2018-12-11 | 蓝印药品公司 | 成纤维细胞生长因子受体的抑制剂 |
| TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
| EP2970231A1 (en) | 2013-03-15 | 2016-01-20 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| WO2015058129A1 (en) | 2013-10-17 | 2015-04-23 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| EP3409674B1 (en) | 2013-10-17 | 2022-04-06 | Blueprint Medicines Corporation | Process for preparing compositions useful for treating disorders related to kit |
| ES2924111T3 (es) | 2013-10-25 | 2022-10-04 | Blueprint Medicines Corp | Inhibidores del receptor del factor de crecimiento de fibroblastos |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| WO2016022569A1 (en) * | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| JP2018521076A (ja) * | 2015-07-24 | 2018-08-02 | ブループリント メディシンズ コーポレイション | Ｋｉｔ及びｐｄｇｆｒに関連する疾病を治療するのに有用な化合物 |
| JP6877407B2 (ja) | 2015-08-26 | 2021-05-26 | ブループリント メディシンズ コーポレイション | Ｎｔｒｋ関連障害の治療に有用な化合物および組成物 |
| WO2017079140A1 (en) | 2015-11-02 | 2017-05-11 | Blueprint Medicines Corporation | Inhibitors of ret |
| JP2019500328A (ja) | 2015-11-19 | 2019-01-10 | ブループリント メディシンズ コーポレイション | Ｎｔｒｋに関連する障害の治療のために有用な化合物及び組成物 |
| UY37155A (es) | 2016-03-17 | 2017-10-31 | Blueprint Medicines Corp | Inhibidores de ret |
| CA3020870C (en) | 2016-04-15 | 2024-04-30 | Blueprint Medicines Corporation | Inhibitors of activin receptor-like kinase |
-
2016
- 2016-07-21 JP JP2018503197A patent/JP2018521076A/ja active Pending
- 2016-07-21 CN CN201680052913.5A patent/CN108026102A/zh active Pending
- 2016-07-21 HK HK18114257.9A patent/HK1255103A1/zh unknown
- 2016-07-21 AU AU2016297754A patent/AU2016297754A1/en not_active Abandoned
- 2016-07-21 BR BR112018001190A patent/BR112018001190A2/pt not_active Application Discontinuation
- 2016-07-21 RU RU2018106483A patent/RU2018106483A/ru not_active Application Discontinuation
- 2016-07-21 WO PCT/US2016/043301 patent/WO2017019442A1/en not_active Ceased
- 2016-07-21 EP EP16745350.5A patent/EP3325481B1/en not_active Not-in-force
- 2016-07-21 MX MX2018001032A patent/MX2018001032A/es unknown
- 2016-07-21 CA CA2994819A patent/CA2994819A1/en not_active Abandoned
- 2016-07-21 KR KR1020187005340A patent/KR20180048635A/ko not_active Withdrawn
- 2016-07-22 US US15/217,503 patent/US10000496B2/en active Active
- 2016-07-22 AR ARP160102250A patent/AR105459A1/es unknown
- 2016-07-23 TW TW105123433A patent/TW201704237A/zh unknown
-
2018
- 2018-01-17 IL IL256978A patent/IL256978A/en unknown
- 2018-01-23 PH PH12018500177A patent/PH12018500177A1/en unknown
- 2018-02-14 ZA ZA2018/01019A patent/ZA201801019B/en unknown
- 2018-05-07 US US15/973,340 patent/US20190119280A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018521076A (ja) | 2018-08-02 |
| AU2016297754A1 (en) | 2018-02-15 |
| WO2017019442A1 (en) | 2017-02-02 |
| EP3325481A1 (en) | 2018-05-30 |
| EP3325481B1 (en) | 2019-06-12 |
| CA2994819A1 (en) | 2017-02-02 |
| MX2018001032A (es) | 2018-11-09 |
| RU2018106483A (ru) | 2019-08-26 |
| CN108026102A (zh) | 2018-05-11 |
| ZA201801019B (en) | 2019-04-24 |
| US10000496B2 (en) | 2018-06-19 |
| KR20180048635A (ko) | 2018-05-10 |
| BR112018001190A2 (pt) | 2018-09-11 |
| HK1255103A1 (zh) | 2019-08-02 |
| PH12018500177A1 (en) | 2018-07-30 |
| IL256978A (en) | 2018-03-29 |
| TW201704237A (zh) | 2017-02-01 |
| US20190119280A1 (en) | 2019-04-25 |
| US20170022206A1 (en) | 2017-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105459A1 (es) | Derivados de pirrolo[2,1-f][1,2,4]triazina útiles para tratar trastornos relacionados con kit y pdfgr | |
| AR105836A1 (es) | Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk | |
| AR106756A1 (es) | Compuestos y composiciones útiles para el tratamiento de trastornos relacionados con ntrk | |
| AR106472A1 (es) | Inhibidores de acc y usos de los mismos | |
| CO2017001603A2 (es) | Compuestos aminopirimidinilo inhibidores de jak | |
| AR107912A1 (es) | Inhibidores de ret | |
| AR089550A1 (es) | Compuestos quimicos | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR110038A1 (es) | Compuestos inhibidores de egfr; composición farmacéutica que lo comprende; métodos para mejorar o tratar un cáncer; método para inhibir la replicación de un crecimiento maligno o un tumor; métodos para inhibir la actividad del egfr; y usos de los compuestos | |
| AR106806A1 (es) | Inhibidores triazol de acc y usos de los mismos | |
| AR101986A1 (es) | Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| AR106798A1 (es) | Inhibidores pirazol de acc y usos de los mismos | |
| AR105893A1 (es) | Derivados del anillo (hetero) aromático sustituidos con carboxi como inhibidores de xantina oxidasa y del transportador 1 del anión urato | |
| AR104388A1 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| AR096242A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR100810A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| PE20190339A1 (es) | 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1 | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR112274A1 (es) | Compuestos bicíclicos de cetona y sus métodos de uso | |
| MX2017011650A (es) | Inhibidores de kv1.3 y su aplicacion medica. | |
| AR107030A1 (es) | Inhibidores aza-bencimidazol de pad4 | |
| AR090376A1 (es) | Compuestos herbicidas | |
| AR099874A1 (es) | CROMENO Y 1,1A,2,7B-TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS COMO MODULADORES DE g-SECRETASA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |